Pharmafile Logo
Pharmafocus logo
Advanced Search

Faslodex

Showing 10 posts of 10 posts found.

pfizerbrussels_web

Pfizer’s Ibrance combo fails to improve overall survival in HER2- metastatic breast cancer

June 26, 2018
Manufacturing and Production, Research and Development, Sales and Marketing AstraZeneca, Faslodex, Pfizer, breast cancer, ibrance, pharma

Pfizer has stumbled with the reveal of new data on the efficacy of its oral CDK 4/6 inhibitor Ibrance (palbociclib) in combination …

News

Faslodex rejected by NICE for NHS breast cancer use

February 2, 2018
Research and Development, Sales and Marketing AstraZeneca, Faslodex, NHS, NICE, UK, pharma

Bad news for breast cancer patients in the UK as the National Institute for Health and Care Excellence announces it …

News
astrazeneca_building_white

NICE rejects AstraZeneca’s breast cancer drug Faslodex

September 1, 2017
Medical Communications, Sales and Marketing AstraZeneca, Cancer, Faslodex, breast cancer, life sciences, pharma, pharmaceutical

NICE has announced its decision to not recommend AstraZeneca’s breast cancer drug Faslodex (fulvestrant) in women who have oestrogen-receptor-positive, locally …

News
astrazeneca_plaque

AstraZeneca’s Faslodex gets US FDA nod in combination treatment for breast cancer

March 8, 2016
Manufacturing and Production, Research and Development AstraZeneca, Faslodex, US FDA, palbociclib

UK drug-maker AstraZeneca said the US Food and Drug Administration (FDA) has approved a new indication expanding the use of …

News

Pfizer breast cancer drug delivers

June 1, 2015
Sales and Marketing ASCO, AZ, Faslodex, Pfizer, breast cancer, brett wells

A Phase III study on Pfizer’s treatment Ibrance in combination with hormone therapy has revealed the drug more than doubled …

News
Faslodex picture

NICE rejects AstraZeneca’s breast cancer drug

December 14, 2011
Sales and Marketing AstraZeneca, Faslodex, NICE

NICE has made its final decision not to recommended AstraZeneca’s breast cancer drug Faslodex, as it says the drug is …

News

NICE won’t back Faslodex in breast cancer

November 10, 2011
Sales and Marketing AstraZeneca, Faslodex, NICE

NICE has not recommended AstraZeneca’s breast cancer drug Faslodex as it says the drug is no better than existing treatments. …

News

NICE blames Faslodex rejection on uncertainties in AZ data

August 23, 2011
Sales and Marketing AstraZeneca, Faslodex, NICE, breast cancer

NICE has not recommended a high-dose form of AstraZeneca’s breast cancer drug Faslodex because of uncertainties over its cost-effectiveness. In …

News

European approval for ‘double strength’ Faslodex

March 19, 2010
Sales and Marketing AstraZeneca, Faslodex, breast cancer

AstraZeneca’s Faslodex has expanded its European licence after winning approval to treat women with hormone receptor-positive breast cancer in a …

News

Faslodex launched in UK

May 19, 2004
AstraZeneca, Faslodex

The latest addition to AstraZeneca’s oncology franchise, breast cancer drug Faslodex has been launched in the UK.Licensed for the treatment …

News

Latest content

BactiVac funds development of bacterial vaccines to prevent infections against antimicrobial resistance

September 28, 2023

Avalyn Pharma raises $175m in Series C financing for inhalation therapies

September 28, 2023

NMD Pharma begins phase 2 trial for spinal muscular atrophy treatment

September 27, 2023

Alfasigma to acquire Intercept Pharmaceuticals for $19 per share

September 27, 2023

Regeneron and Sanofi’s sBLA for Dupixent accepted by FDA for priority review

September 26, 2023